ARFXF - ARFXF STOCK NEWS

ProMIS Neurosciences Inc. (OTCQB: ARFXF) held its Annual and Special Meeting of Shareholders on May 12, 2022, with 45.13% of Common Shares represented. All proposed resolutions were approved, including the election of eight directors, the appointment of PricewaterhouseCoopers as auditor, and amendments to the By-Laws for increased quorum requirements. Directors received high support, with votes for ranging from 84.04% to 99.12%. The company, focused on antibody therapeutics for neurodegenerative diseases, continues to develop innovative treatments targeting toxic oligomers.

ProMIS Neurosciences (OTCQB: ARFXF) announced progress in developing therapeutics targeting misfolded proteins related to ALS. Their lead candidate, monoclonal antibody PMN267, shows promise in reducing neurotoxic TDP-43 aggregates in human motor neurons and demonstrated protective effects against disability in mouse models. These findings have been supported by independent studies from UC San Diego and a contract research organization. Additionally, the company has made strides in targeting RACK1, another protein implicated in ALS.

ProMIS Neurosciences has appointed Larry Altstiel, M.D., Ph.D., as Chief Medical Officer, bringing over two decades of experience in Alzheimer’s research from major pharmaceutical companies. His expertise is expected to enhance ProMIS's focus on antibody therapeutics targeting misfolded proteins in neurodegenerative diseases, particularly Alzheimer’s and ALS. Altstiel’s background includes leadership in clinical research at Pfizer and significant academic credentials. This strategic hire aims to strengthen the company’s innovations and product pipeline.

Argus Research has initiated coverage on ProMIS Neurosciences (TSX: PMN; OTCQB: ARFXF), a biotech firm focusing on therapeutic antibodies for neurodegenerative diseases, like Alzheimer's and ALS. The report emphasizes ProMIS' proprietary algorithms and 100% success rate in generating antibodies against disease-specific targets. Their lead candidate, PMN310, is set to begin a Phase 1b trial in early 2023 following promising preclinical results. The company expects to maintain financial stability with C$21.5 million in funding through 2023, despite anticipated increases in capital needs.

ProMIS Neurosciences has announced the mailing of the Notice-and-Access (N&A Notice) to shareholders ahead of its Annual General and Special Meeting scheduled for May 12, 2022. Shareholders of record as of April 1, 2022, can access the meeting materials on the Corporation’s website and SEDAR. The meeting will cover the election of directors, the appointment of an auditor, and amendments to the Corporation's By-Laws regarding quorum requirements. The Board recommends shareholders vote in favor of all proposals.

ProMIS Neurosciences, a biotechnology firm focused on therapeutics for neurodegenerative diseases, presented research at the American Academy of Neurology Annual Meeting (April 2-7, 2022). Dr. Beibei Zhao showcased findings on RACK1 knockdown's potential benefits against TDP-43-related pathology, suggesting a pathogenic interaction with neurodegeneration. This work underscores ProMIS's innovative approach to tackling diseases like ALS, Alzheimer's, and Parkinson's through its proprietary target discovery platform. Further details are accessible on ProMIS's website and the AAN portal.

ProMIS Neurosciences, a biotechnology company, will present at the 10th Annual Neurodegenerative Drug Development Summit in Boston from March 28-30, 2022. Chief Scientific Officer Dr. Neil Cashman will discuss targeting misfolded proteins, particularly amyloid beta oligomers related to Alzheimer’s disease, in his presentation titled “Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction” on March 29 at 3 PM. The presentation focuses on a proprietary computational algorithm, Collective Coordinates, to design conformational epitopes for selective targeting. For details, visit ProMIS Neurosciences.

ProMIS Neurosciences has made significant strides in developing a novel Alzheimer's vaccine targeting toxic amyloid-beta oligomers (AβO). Presenting at the AD/PD™ Conference, the Chief Development Officer, Dr. Johanne Kaplan, highlighted the vaccine's ability to elicit antibodies specifically against AβO while avoiding detrimental immune responses to normal Aβ forms. Initial tests in mice have indicated robust antibody production with limited inflammatory responses, paving the way for further development. The proprietary computational modeling used in the vaccine design showcases ProMIS's innovative approach to tackling neurodegenerative diseases.

ProMIS Neurosciences, focusing on antibody therapeutics for neurodegenerative diseases, reported its financial results for FY 2021. Revenue surged to $16,410 due to royalties, up from $1,787 in 2020. However, the net loss increased to $11.78 million compared to $5.66 million the previous year. R&D expenses rose significantly to $6.31 million, driven by contract research increases. The company has secured funds for operations through 2023 and is advancing programs for Alzheimer's (PMN310) and ALS (PMN267), with promising preclinical results expected in 2022.